Skip to main content
Erschienen in: Molecular Imaging and Biology 3/2020

27.06.2019 | Research Article

Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis

verfasst von: Aimi Zhang, Tianze Wu, Li Bian, Panli Li, Qiufang Liu, Dongjian Zhang, Qiaomei Jin, Jian Zhang, Gang Huang, Shaoli Song

Erschienen in: Molecular Imaging and Biology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to synthesize a necrosis-avid agent using rhein as a precursor and labeled with gallium-68 (Ga-68) for positron emission tomography/computed tomography (PET/CT) imaging, to evaluate response to anticancer treatment in a mouse model.

Procedures

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–conjugated rhein was radiolabeled with Ga-68 to formulate [68Ga]DOTA-rhein. The in vitro stability of [68Ga]DOTA-rhein was assessed by radio-HPLC. Necrosis avidity was evaluated in a mouse model of muscle necrosis by microPET/CT imaging, biodistribution study, histochemical staining, and autoradiography studies. Murine tumor models with the subcutaneous implantation of S180 cell lines were generated for the evaluation of therapeutic effect. Tumor necrosis was induced by the treatment of combretastatin A4 disodium phosphate (CA4P), and microPET/CT imaging was performed at 1 h post tracer injection. DNA binding studies were conducted to explore the necrosis avidity mechanism of the tracer.

Results

[68Ga]DOTA-rhein exhibited a satisfactory yield, a radiochemical purity over 97 %, and a good serum stability. The uptakes of [68Ga]DOTA-rhein in necrotic muscles and tumors were significantly higher than those in normal muscles and tumors (P < 0.05). The results of autoradiography and histochemical staining were consistent with the selective uptake of the radiotracer in necrotic regions. MicroPET/CT images showed a high uptake of the tracer in necrotic muscles and necrotic tumors. DNA binding studies suggested that necrosis avidity correlated with DNA binding to a certain extent.

Conclusions

Our results demonstrated that [68Ga]DOTA-rhein showed a prominent necrosis avidity and could be a useful probe for early assessment of response to anticancer therapy by PET/CT imaging.
Literatur
1.
Zurück zum Zitat De Saint-Hubert M, Prinsen K, Mortelmans L et al (2009) Molecular imaging of cell death. Methods 48:178–187CrossRef De Saint-Hubert M, Prinsen K, Mortelmans L et al (2009) Molecular imaging of cell death. Methods 48:178–187CrossRef
2.
Zurück zum Zitat Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRef Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRef
3.
Zurück zum Zitat Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 87:881–886PubMed Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 87:881–886PubMed
4.
Zurück zum Zitat Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 39:2012–2020CrossRef Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 39:2012–2020CrossRef
5.
Zurück zum Zitat Pysz MA, Gambhir SS, Willmann JK (2010) Molecular imaging: current status and emerging strategies. Clin Radiol 65:500–516CrossRef Pysz MA, Gambhir SS, Willmann JK (2010) Molecular imaging: current status and emerging strategies. Clin Radiol 65:500–516CrossRef
6.
Zurück zum Zitat Ji Y, Jiang C, Zhang X et al (2014) Necrosis targeted combinational theragnostic approach to treat cancer. Oncotarget 5:2934CrossRef Ji Y, Jiang C, Zhang X et al (2014) Necrosis targeted combinational theragnostic approach to treat cancer. Oncotarget 5:2934CrossRef
7.
Zurück zum Zitat Jiang B, Wang J, Ni Y, Chen F (2013) Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics 3:667–676CrossRef Jiang B, Wang J, Ni Y, Chen F (2013) Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics 3:667–676CrossRef
8.
9.
Zurück zum Zitat Galluzzi L, Vitale I, Abrams J et al (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19:107–120CrossRef Galluzzi L, Vitale I, Abrams J et al (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19:107–120CrossRef
10.
Zurück zum Zitat Cona MM, Oyen R, Ni Y (2015) Necrosis avidity of organic compounds: a natural phenomenon with exploitable theragnostic potentials. Curr Med Chem 22:1829–1849CrossRef Cona MM, Oyen R, Ni Y (2015) Necrosis avidity of organic compounds: a natural phenomenon with exploitable theragnostic potentials. Curr Med Chem 22:1829–1849CrossRef
11.
Zurück zum Zitat Van de Putte M, Marysael T, Fonge H et al (2012) Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer 131:E129–E137CrossRef Van de Putte M, Marysael T, Fonge H et al (2012) Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer 131:E129–E137CrossRef
12.
Zurück zum Zitat Park D, Xie B-W, Van Beek ER et al (2013) Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator. Mol Pharm 10:3882–3891CrossRef Park D, Xie B-W, Van Beek ER et al (2013) Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator. Mol Pharm 10:3882–3891CrossRef
13.
Zurück zum Zitat Li J, Zhang J, Yang S et al (2015) Synthesis and preclinical evaluation of radioiodinated hypericin dicarboxylic acid as a necrosis avid agent in rat models of induced hepatic, muscular, and myocardial necroses. Mol Pharm 13:232–240CrossRef Li J, Zhang J, Yang S et al (2015) Synthesis and preclinical evaluation of radioiodinated hypericin dicarboxylic acid as a necrosis avid agent in rat models of induced hepatic, muscular, and myocardial necroses. Mol Pharm 13:232–240CrossRef
14.
Zurück zum Zitat Flotats A, Carrió I (2003) Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 30:615–630CrossRef Flotats A, Carrió I (2003) Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 30:615–630CrossRef
15.
Zurück zum Zitat Khaw BA, Haber E (1989) Imaging necrotic myocardium: detection with 99mTc-pyrophosphate and radiolabeled antimyosin. Cardiol Clin 7:577–588CrossRef Khaw BA, Haber E (1989) Imaging necrotic myocardium: detection with 99mTc-pyrophosphate and radiolabeled antimyosin. Cardiol Clin 7:577–588CrossRef
16.
Zurück zum Zitat Liu X, Jiang C, Li Y, Liu W, Yao N, Gao M, Ji Y, Huang D, Yin Z, Sun Z, Ni Y, Zhang J (2015) Evaluation of hypericin: effect of aggregation on targeting biodistribution. J Pharm Sci 104:215–222CrossRef Liu X, Jiang C, Li Y, Liu W, Yao N, Gao M, Ji Y, Huang D, Yin Z, Sun Z, Ni Y, Zhang J (2015) Evaluation of hypericin: effect of aggregation on targeting biodistribution. J Pharm Sci 104:215–222CrossRef
17.
Zurück zum Zitat Ji Y, Zhan Y, Jiang C, Jiang X, Gao M, Liu W, Li Y, Wang J, Wang Q, Cona MM, Yao N, Wang X, Fang Z, Yin Z, Zhang J, Sun Z, Ni Y (2014) Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target 22:304–312CrossRef Ji Y, Zhan Y, Jiang C, Jiang X, Gao M, Liu W, Li Y, Wang J, Wang Q, Cona MM, Yao N, Wang X, Fang Z, Yin Z, Zhang J, Sun Z, Ni Y (2014) Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target 22:304–312CrossRef
18.
Zurück zum Zitat Evans WC (2009) Trease and Evans’ pharmacognosy e-book. Elsevier Health Sciences, Edinburgh Evans WC (2009) Trease and Evans’ pharmacognosy e-book. Elsevier Health Sciences, Edinburgh
19.
Zurück zum Zitat Yu L, Xiang H, Fan J et al (2008) Global transcriptional response of Staphylococcus aureus to rhein, a natural plant product. J Biotechnol 135:304–308CrossRef Yu L, Xiang H, Fan J et al (2008) Global transcriptional response of Staphylococcus aureus to rhein, a natural plant product. J Biotechnol 135:304–308CrossRef
20.
Zurück zum Zitat Joung D-K, Joung H, Yang D-W et al (2012) Synergistic effect of rhein in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. Exp Ther Med 3:608–612CrossRef Joung D-K, Joung H, Yang D-W et al (2012) Synergistic effect of rhein in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. Exp Ther Med 3:608–612CrossRef
21.
Zurück zum Zitat La Villa G, Marra F, Laffi G et al (1989) Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure. Eur J Clin Pharmacol 37:1–5CrossRef La Villa G, Marra F, Laffi G et al (1989) Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure. Eur J Clin Pharmacol 37:1–5CrossRef
22.
Zurück zum Zitat Bian L, Gao M, Zhang D, Ji A, Su C, Duan X, Luo Q, Huang D, Feng Y, Ni Y, Yin Z, Jin Q, Zhang J (2018) Synthesis and biological evaluation of rhein-based MRI contrast agents for in vivo visualization of necrosis. Anal Chem 90:13249–13256CrossRef Bian L, Gao M, Zhang D, Ji A, Su C, Duan X, Luo Q, Huang D, Feng Y, Ni Y, Yin Z, Jin Q, Zhang J (2018) Synthesis and biological evaluation of rhein-based MRI contrast agents for in vivo visualization of necrosis. Anal Chem 90:13249–13256CrossRef
23.
Zurück zum Zitat Luo Q, Jin Q, Su C et al (2016) Radiolabeled rhein as small-molecule necrosis avid agents for imaging of necrotic myocardium. Anal Chem 89:1260–1266CrossRef Luo Q, Jin Q, Su C et al (2016) Radiolabeled rhein as small-molecule necrosis avid agents for imaging of necrotic myocardium. Anal Chem 89:1260–1266CrossRef
24.
Zurück zum Zitat Wang Q, Yang S, Jiang C, Li J, Wang C, Chen L, Jin Q, Song S, Feng Y, Ni Y, Zhang J, Yin Z (2016) Discovery of radioiodinated monomeric anthraquinones as a novel class of necrosis avid agents for early imaging of necrotic myocardium. Sci Rep 6:21341CrossRef Wang Q, Yang S, Jiang C, Li J, Wang C, Chen L, Jin Q, Song S, Feng Y, Ni Y, Zhang J, Yin Z (2016) Discovery of radioiodinated monomeric anthraquinones as a novel class of necrosis avid agents for early imaging of necrotic myocardium. Sci Rep 6:21341CrossRef
25.
Zurück zum Zitat Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, Rubello D, Fanti S (2012) PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 81:988–1001CrossRef Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, Rubello D, Fanti S (2012) PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 81:988–1001CrossRef
26.
Zurück zum Zitat Ambrosini V, Fanti S (2014) 68Ga-DOTA-peptides in the diagnosis of NET. PET clinics 9:37–42CrossRef Ambrosini V, Fanti S (2014) 68Ga-DOTA-peptides in the diagnosis of NET. PET clinics 9:37–42CrossRef
27.
Zurück zum Zitat Ceci F, Castellucci P, Cerci JJ, Fanti S (2017) New aspects of molecular imaging in prostate cancer. Methods 130:36–41CrossRef Ceci F, Castellucci P, Cerci JJ, Fanti S (2017) New aspects of molecular imaging in prostate cancer. Methods 130:36–41CrossRef
28.
Zurück zum Zitat Fei B-L, Xu W-S, Gao W-L, Zhang J, Zhao Y, Long JY, Anson CE, Powell AK (2015) DNA binding and cytotoxicity activity of a chiral iron (III) triangle complex based on a natural rosin product. J Photochem Photobiol B Biol 142:77–85CrossRef Fei B-L, Xu W-S, Gao W-L, Zhang J, Zhao Y, Long JY, Anson CE, Powell AK (2015) DNA binding and cytotoxicity activity of a chiral iron (III) triangle complex based on a natural rosin product. J Photochem Photobiol B Biol 142:77–85CrossRef
29.
Zurück zum Zitat Prinsen K, Li J, Vanbilloen H, Vermaelen P, Devos E, Mortelmans L, Bormans G, Ni Y, Verbruggen A (2010) Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorg Med Chem 18:5274–5281CrossRef Prinsen K, Li J, Vanbilloen H, Vermaelen P, Devos E, Mortelmans L, Bormans G, Ni Y, Verbruggen A (2010) Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorg Med Chem 18:5274–5281CrossRef
30.
Zurück zum Zitat Prinsen K, Cona MM, Cleynhens BJ, Li J, Vanbilloen H, Dyubankova N, Lescrinier E, Ni Y, Bormans GM, Verbruggen AM (2013) Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis. Nucl Med Biol 40:816–822CrossRef Prinsen K, Cona MM, Cleynhens BJ, Li J, Vanbilloen H, Dyubankova N, Lescrinier E, Ni Y, Bormans GM, Verbruggen AM (2013) Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis. Nucl Med Biol 40:816–822CrossRef
31.
Zurück zum Zitat Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity. Investig Radiol 40:526–535CrossRef Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity. Investig Radiol 40:526–535CrossRef
32.
Zurück zum Zitat Ni Y, Chen F, Mulier S, Sun X, Yu J, Landuyt W, Marchal G, Verbruggen A (2006) Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. Eur Radiol 16:1031–1040CrossRef Ni Y, Chen F, Mulier S, Sun X, Yu J, Landuyt W, Marchal G, Verbruggen A (2006) Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. Eur Radiol 16:1031–1040CrossRef
33.
Zurück zum Zitat Matsumori A, Yamada T, Sasayama S (1996) Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Int J Cardiol 54:183–190CrossRef Matsumori A, Yamada T, Sasayama S (1996) Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Int J Cardiol 54:183–190CrossRef
34.
Zurück zum Zitat Kong M, Zhang J, Jiang C, Jiang X, Li Y, Gao M, Yao N, Huang D, Wang X, Fang Z, Liu W, Sun Z, Ni Y (2013) Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis. J Drug Target 21:604–610CrossRef Kong M, Zhang J, Jiang C, Jiang X, Li Y, Gao M, Yao N, Huang D, Wang X, Fang Z, Liu W, Sun Z, Ni Y (2013) Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis. J Drug Target 21:604–610CrossRef
35.
Zurück zum Zitat Prinsen K, Cona MM, Cleynhens J, Vanbilloen H, Li J, Dyubankova N, Lescrinier E, Bormans G, Ni Y, Verbruggen A (2013) Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3, 3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis. Bioorg Med Chem Lett 23:3216–3220CrossRef Prinsen K, Cona MM, Cleynhens J, Vanbilloen H, Li J, Dyubankova N, Lescrinier E, Bormans G, Ni Y, Verbruggen A (2013) Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3, 3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis. Bioorg Med Chem Lett 23:3216–3220CrossRef
36.
Zurück zum Zitat Sosabowski JK, Mather SJ (2006) Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc 1:972–976CrossRef Sosabowski JK, Mather SJ (2006) Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc 1:972–976CrossRef
37.
Zurück zum Zitat Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott R, Suckow MA, Johnson JR, Piwnica-Worms D, Gokel GW, Smith BD, Leevy WM (2011) In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc− dipicolylamine probe. Mol Pharm 8:583–590CrossRef Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott R, Suckow MA, Johnson JR, Piwnica-Worms D, Gokel GW, Smith BD, Leevy WM (2011) In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc− dipicolylamine probe. Mol Pharm 8:583–590CrossRef
38.
Zurück zum Zitat Woods J, Hadfield JA, Pettit G, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71:705–711CrossRef Woods J, Hadfield JA, Pettit G, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71:705–711CrossRef
39.
Zurück zum Zitat Ng Q-S, Mandeville H, Goh V et al (2011) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23:231–237CrossRef Ng Q-S, Mandeville H, Goh V et al (2011) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23:231–237CrossRef
Metadaten
Titel
Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis
verfasst von
Aimi Zhang
Tianze Wu
Li Bian
Panli Li
Qiufang Liu
Dongjian Zhang
Qiaomei Jin
Jian Zhang
Gang Huang
Shaoli Song
Publikationsdatum
27.06.2019
Verlag
Springer International Publishing
Erschienen in
Molecular Imaging and Biology / Ausgabe 3/2020
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01365-y

Weitere Artikel der Ausgabe 3/2020

Molecular Imaging and Biology 3/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.